Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy’s US launch, the Danish drugmaker’s growth is slowing. About one million patients in the US are taking cheaper copycat options. To reverse this decline, Novo named a new chief executive this week to win them back – and prove the company can still compete with US rival Eli Lilly & Co.
Visited 1 times, 1 visit(s) today
